◼ Archived
Business
‘Zap, you’re gone.’ A Dana-Farber oncologist discusses the promising news on cancer vaccines.
Moderna and Merck's mRNA cancer vaccine reduces melanoma recurrence by 42% according to recent coverage.
Dana-Farber
7 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
Moderna CEO on what’s next after success in cancer vaccine
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
Boston is getting a new cancer hospital. Here’s what Dana-Farber's $1.7B project means for patients
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
Dana-Farber, Beth Israel begin construction of new $1.68 billion cancer hospital
Construction begins on the Lavine Bekenstein Cancer Hospital following a major groundbreaking announcement.
◼ Archived
Health
🔮 fades ✓
‘Collateral damage’: Mass General Brigham Health Plan removes Dana-Farber from its Medicare Advantage network
Mass General Brigham Health Plan has removed Dana-Farber from its Medicare Advantage network, leaving cancer patients facing disrupted care.
◼ Archived
Business
🔮 fades ✓
'These Are Exciting Times' in the Cancer Fight
Recent FDA approval of daraxonrasib for metastatic pancreatic cancer brings new hope to patients and clinicians alike.
◼ Archived
Health
🔮 fades
A Bayesian framework for longitudinal EHR and genetic discovery
Researchers have developed a Bayesian framework that integrates longitudinal EHR data and genetics to predict hundreds of different diseases.